|Day Low/High||41.08 / 41.30|
|52 Wk Low/High||36.41 / 42.32|
Johnson & Johnson replaces Merck in AAP given better pipeline and stock upside potential, says AAP Co-Portfolio Manager, Stephanie Link.
U.S. stock futures are pointing to a higher open as Obama presses case for military action in Syria.
GlaxoSmithKline revealed that some of its senior executives in China may have broken the law.
Jim Cramer and Stephanie Link, Co-Portfolio Managers of AAP, discuss how they are trading the current bull market.
Luxury homebuilder Toll Brothers reported better-than-expected second quarter earnings on increased demand for new homes.
You can't get away from the need for good yield in an era of commodity inflation.
Let's look at five holdings that stayed in his portfolio for at least a year.
General Electric reports a first quarter profit rising 16%, meeting estimates. Brittany Umar details that and the morning's other top news.
TheStreet's Jim Cramer says Abbott Labs will benefit from growth in emerging markets and Glaxo will benefit from a "huge pipeline of approvals." The Action Alerts Plus portfolio recently bought Glaxo shares and added to their position in Abbott Labs.
Jim Cramer looks at why he is highlighting pharma along with growth biotech, with Nicole Urken, Mad Money Research Associate.
Klarman's hedge funds' top small-cap picks generate significant alpha.
Senior columnist Adam Feuerstein says Dynavax Technologies is the next big thing to watch in biotech.
Marek Fuchs, senior contributing analyst at TheStreet, talks proportion on Glaxo.
Simon Dingemans, CFO of GlaxoSmithKline, discusses the company's bid for Human Genome, Obamacare and the company's growing emerging-market business.
Adrian Adams, CEO of Auxilium, discusses the company's breakthrough with Xiaflex, as well as recent news surrounding its drug Testim.
A look at the day's most searched trends on the Web, including GlaxoSmithKline's intentions to take its bid for Human Genome Sciences hostile.
Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.
Aviat, Capstone and Axcelis are high-reward/high-risk plays for under $2.50.
A look at the day's most searched topics on the Web, including the European Union's approval of Johnson & Johnson's $21.3 billion takeover of Synthes.
Biotech is changing, so here's how to invest amid the industry's new gold rush.
If you need to live on investment income, bonds and CDs are not enough -- you need dividends.
The damage to a big drug's approval odds is much less than is presently priced into LGND.